Gastrointestinal cancer
Conditions
Interventions
Index test:Fluoride [18F] Fibrostatin Injection PET/CT
Sponsors
the First Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Those who meet all of the following conditions are eligible for selection: (1) Age = 18 years old; (2) Pathologically confirmed gastrointestinal tumor and planned surgical resection/exploration patients (including primary or recurrent metastatic tumors in the gastrointestinal tract); (3) Received enhanced CT examination of the lesion site within two weeks; (4) According to the doctor's judgment, the expected survival period is>3 months; (5) Voluntarily sign an informed consent form; Willing and able to follow the research protocol.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria are not eligible for enrollment: (1) Individuals with a known history of allergies to fluoride [18F] and/or endostatin injection or its excipients; (2) Those who cannot tolerate intravenous administration methods (such as a history of needle or blood sickness); Researchers believe that imaging examinations such as PET are not suitable or cannot be completed due to special reasons, including claustrophobia, radiation phobia, etc; (3) Patients who have received anti-tumor therapy before examination, or who have received neoadjuvant chemotherapy/targeted therapy for tumor reduction from examination to surgery; (4) Pregnant and lactating women; (5) Practitioners who require long-term exposure to radioactive conditions; (6) Serious diseases such as heart, kidney, lungs, blood vessels, nerves, and mental systems, immune deficiency diseases, and hepatitis/cirrhosis; (7) Participated in other interventional clinical trials within one month prior to screening; (8) Patients undergoing chemotherapy, immunotherapy, or molecular targeted therapy; (9) There are other situations where the researcher believes it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax;Percentage of positive patients;Percentage of positive lesions in total evaluated lesions;sensitiveness;specificity;accuracy; | — |
Countries
China
Contacts
Public ContactJing Wang
the First Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
Outcome results
None listed